成纤维母细胞生长因子23与慢性肾脏病患者血磷异常的研究进展  

Research Progress on the Relationship between Fibroblast Growth Factor 23 and Disturbance of Phosphorus Metabolism in Patients with Chronic Kidney Disease

作　　者：刘其锋[1] 李莎莎[2] 叶建明[1] 

机构地区：[1]江苏大学附属昆山医院肾脏内科,江苏昆山215300 [2]江苏大学附属昆山医院中心实验室,江苏昆山215300

出　　处：《医学综述》2015年第10期1751-1753,共3页Medical Recapitulate

摘　　要：磷代谢紊乱是慢性肾脏病(CKD)患者预后独立危险因素,也是药物治疗的靶点。成纤维母细胞生长因子23是新发现的调节血磷代谢的激素,它通过抑制肾脏对磷的重吸收,促进尿磷排泄,从而降低血磷。成纤维母细胞生长因子不仅参与维持生理状态下血磷的调节,也与CKD患者的磷代谢异常有关。CKD患者的高血磷会导致成纤维母细胞生长因子23水平的明显升高,不仅反映CKD患者的血磷聚集,也是继发性甲状旁腺功能亢进症及CKD的进展、预后的一个重要预测因子,并可能成为治疗CKD患者磷代谢紊乱的新靶点。Disturbance of phosphorous metabolism is an independent risk factor of the prognosis in patients with chronic kidney disease（CKD）,and it is also the target for pharmacological intervention.Fibro-blast growth factor 23 is a recently identified hormone that regulates serum phosphorous metabolism and prin-cipally acts in the kidney to induce urinary phosphate excretion to maintain phosphate homeostasis .Fibroblast growth factor 23 is not only involved in regulating serum phosphorous metabolism under physiological condi-tion,but also related with disturbance of phosphorus metabolic in patients with CKD.Fibroblast growth factor 23 levels in CKD patients are markedly elevated in response to hyperphosphatemia ,that it indicates the phos-phorus accumulation in CKD patients.Therefore, fibroblast growth factor 23 can be a predictor for the pro-gression and prognosis of secondary hyperparathyroidism and CKD,as well as a new target in the treatment for disturbance of phosphorous metabolism in CKD patients.

关 键 词：慢性肾脏病 成纤维母细胞生长因子23 磷 

分 类 号：R692.5[医药卫生—泌尿科学]